Overview

Our MAGE-A10 T-cell therapy is directed to a highly immunogenic member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors.

Based on our ongoing preclinical evaluation, we believe our MAGE-A10 TCR therapeutic candidate has the potential ability to bind target peptides from multiple cancer types. Clinical trials to evaluate the safety and anti-tumor activity of our MAGE-A10 TCR therapy are open for certain patients with lung cancer, bladder, melanoma and head and neck cancers.

Pipeline

Program Indications Pre-Clinical Phase I/II Registration
MAGE-A10 Urothelial
Melanoma
Head & Neck
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
NSCLC (lung)
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started

Learn More About